560P Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC

达布拉芬尼 医学 奥西默替尼 曲美替尼 癌症研究 突变体 肿瘤科 突变 靶向治疗 内科学 表皮生长因子受体 激酶 埃罗替尼 MAPK/ERK通路 基因 威罗菲尼 遗传学 癌症 黑色素瘤 生物 转移性黑色素瘤
作者
C. Weng,Kejing Tang,Shijie Jin,Chenfei Zhou,Yueliang Yao,J-W. Su,Huarong Chen,Kan Liu,Yuan Li,Jin‐Ji Yang
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1688-S1688
标识
DOI:10.1016/j.annonc.2023.10.638
摘要

This study represents, to our knowledge, the first cohort study investigation into the efficacy and safety of a triple-targeted therapy comprising EGFR/BRAF/MEK inhibitors dabrafenib, trametinib and osimertinib for NSCLC patients with acquired BRAF V600E mutation after EGFR-TKI treatment. Patient-derived organoid (PDO) experiments were conducted to further elucidate the drug response. A retrospective review of medical records was performed in multi-centers to analyze EGFR-mutant advanced NSCLC patients who developed acquired BRAF V600E mutation following EGFR-TKI treatment. All patients subsequently received dabrafenib, trametinib and osimertinib treatment. Clinical characteristics were documented, and progression-free survival (PFS) and adverse events (AEs) were assessed. In vivo drug response of PDOs were observed concurrently. Next-generation sequencing (NGS) was performed upon progression to triple-targeted therapy. Twelve patients with NGS-detected acquired BRAF V600E mutations were included in the study. Following triple-targeted therapy, the corresponding objective response rate (ORR) and disease control rate (DCR) was 58.3%, and 83.3%, respectively. The median PFS was 13.5 (95% CI: 9.8-17.2) months. No patients discontinued the treatment due to severe AEs. PDOs derived from one patient’s tumor sample were established, revealing that the triple-targeted therapy demonstrated a significantly lower IC50 value compared to other regimens. The tumor growth inhibitory rate was 99.36% for dabrafenib, trametinib plus osimertinib, 99.25% for osimertinib plus vemurafenib, 98.92% for osimertinib, encorafenib plus cetuximab, and 62.83% for pemetrexed plus carboplatin, respectively. NGS analysis identified major resistance mechanism following triple-targeted therapy, including EGFR-dependent pathway, EGFR and BRAF V600E-dependent pathway, and off-target mechanism. EGFR/BRAF/MEK triple-targeted therapy is an effective and safety approach for treating acquired BRAF V600E mutation in EGFR-mutant NSCLC patients resistant to EGFR-TKIs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
知性的剑身完成签到,获得积分10
1秒前
1秒前
热心市民小红花应助清零采纳,获得10
1秒前
2秒前
汉堡包应助还原糖采纳,获得10
2秒前
森林完成签到,获得积分10
3秒前
WJ完成签到,获得积分20
4秒前
江沅完成签到,获得积分10
4秒前
小超超发布了新的文献求助10
4秒前
4秒前
敏感的盼夏完成签到,获得积分10
4秒前
5秒前
5秒前
5秒前
Philiadddd发布了新的文献求助30
5秒前
6秒前
Owen应助Kombate采纳,获得10
7秒前
7秒前
7秒前
WJ发布了新的文献求助10
8秒前
研友_8op5gL发布了新的文献求助10
8秒前
wyx完成签到,获得积分10
10秒前
甜甜玫瑰发布了新的文献求助10
11秒前
SciGPT应助宋宋采纳,获得10
11秒前
帕荣荣发布了新的文献求助10
11秒前
ZLY发布了新的文献求助10
12秒前
12秒前
huhu发布了新的文献求助10
13秒前
852应助科研通管家采纳,获得10
13秒前
大模型应助科研通管家采纳,获得10
13秒前
脑洞疼应助科研通管家采纳,获得10
13秒前
FashionBoy应助科研通管家采纳,获得10
14秒前
14秒前
深情安青应助科研通管家采纳,获得10
14秒前
Ava应助科研通管家采纳,获得10
14秒前
李爱国应助小韩采纳,获得10
14秒前
Akim应助科研通管家采纳,获得10
14秒前
SciGPT应助科研通管家采纳,获得10
14秒前
所所应助科研通管家采纳,获得10
14秒前
Hello应助科研通管家采纳,获得10
14秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975814
求助须知:如何正确求助?哪些是违规求助? 3520123
关于积分的说明 11201020
捐赠科研通 3256502
什么是DOI,文献DOI怎么找? 1798347
邀请新用户注册赠送积分活动 877523
科研通“疑难数据库(出版商)”最低求助积分说明 806417